



<b>NEURON BPh:</b> <i>Hybrid Biotechnology</i>	OECD Meeting Seville, 2011
	

<p><b>NEURON DESCRIPTION</b></p> <ul style="list-style-type: none"><li>• Spanish biotech company, located at <b>Granada's</b> Health-Science Technological Park + commercial office in <b>Florida</b> (US).</li><li>• <b>Spin-off</b> from the Universidad Autonoma de Madrid</li><li>• Business activity started in September 2006.</li><li>• <b>45-people staff</b> : 17 Ph.Ds.</li><li>• <b>37 agreements with public research groups</b> (Universities from Granada, Almeria, Seville, Malaga, Jaen, Madrid, Barcelona,, Leon, etc).</li><li>• <b>IP: 7 patent applications + 4 exclusive licensee</b></li></ul>	
--	--

# NEURON

BPh

Since 1 July 2010 **Neuron BPh** is quoted on the Spanish Alternative **Stock Market (MAB)**

- IPO: 2,5 M€
- **First biotech company** in the MAB
- Only **Andalusian** company in this market
- Only company to trade on the **continuous** market
- **More than 2,500 shareholders** (Universities, National Alzheimer's Association, banks, staff, small investors...)
- Market capitalization: **14 – 18 M€**



# NEURON

BPh

## Business Model



### TOYOTA PRIUS:

Hybrid engine combining:

- fuel economy
- acceleration when needed
- environmentally friendly

# NEURON

BPh

## Business Model

- Business model: **(Bio)Technology licensor**

- **BioPharma:** discovery and development of neuroprotectants

- From discovery to Phase II clinical trial.
- Co-development or out-license.
- Potential high long-term revenues from out-license agreements

- **BioIndustrial:** development of industrial bioprocesses.


- From microliters to industrial scale.
- Out-license of technologies.
- Turn key projects.
- Benefits from year 1 by contractual research agreements with important food and biofuel companies (Grupo SOS, REPSOL, ABENGOA...).

- **Synergies:**

- Pharmaceutical know-how applied to bioindustrial applications
- Shared equipment and biotechnological "toolbox"


**NEURON**  
BPh

## Financing biotech companies





**NEURON**  
BPh

**Neuroprotective compounds**




**MicroBioOil®**






**Microbial Biodiversity**


**Nutraceuticals: DHA**



**TriBioPlast®**




- Exclusive collection of over **8.000 microbial strains** (filamentous fungi, bacteria, yeast, microalgae...) with industrial applications
- Improved culturing techniques and growth conditions to obtain new species and genera of microorganisms



## UGR and NEURON

- Neuron BPh and the University of Granada signed in 2007 a framework agreement for the development of biomedical research projects. Under this agreement NEURON BPh transferred to the University of Granada 1% of its shares.
- Join activities in the fields of **pharmacodynamics** and **analytical chemistry** focused on the discovery of new drugs for Alzheimer disease.
- This agreement regulates the use of **technical tools** (animal facilities, lab equipment, etc) between NEURON and academic researchers.
- Collaboration for the **incorporation of UGR's students to the company** (Job Applicants database & Selection).
- Collaboration in the **EC funded project NUTRIMENTHE** studying the effect of early nutrition on the mental development of children (Scientific leadership of UGR).



## Next steps

1. Close partnership deals for NST0037 development.
2. Take novel lead compounds to clinical stages and fuel our pipeline.
3. Scale-up industrial bioprocesses to demonstration plants.

**NEURON**  
BPh

## NEURON's Building



**NEURON**  
BPh